These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1560366)

  • 21. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH; Milhahn H; Eich E
    J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative 5-HT2-receptor antagonist activity of amesergide and its active metabolite 4-hydroxyamesergide in rats and rabbits.
    Cohen ML; Kurz KD; Fuller RW; Calligaro DO
    J Pharm Pharmacol; 1994 Mar; 46(3):226-9. PubMed ID: 8027933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.
    Rinaldi-Carmona M; Congy C; Santucci V; Simiand J; Gautret B; Neliat G; Labeeuw B; Le Fur G; Soubrie P; Breliere JC
    J Pharmacol Exp Ther; 1992 Aug; 262(2):759-68. PubMed ID: 1501121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological profile of a new 5-hydroxytryptamine2 receptor antagonist, DV-7028.
    Shibano T; Tanaka T; Morishima Y; Yasuoka M; Watanabe K; Fujii F
    Arch Int Pharmacodyn Ther; 1992; 319():114-28. PubMed ID: 1285670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets.
    Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
    Hamel E; Robert JP; Young AR; MacKenzie ET
    J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190.
    Cohen ML; Bloomquist W; Schaus JM; Thompson DC; Susemichel AD; Calligaro DA; Cohen I
    J Pharmacol Exp Ther; 1996 Apr; 277(1):97-104. PubMed ID: 8613972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML; Schenck K
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle.
    Cohen ML; Schenck KW; Colbert W; Wittenauer L
    J Pharmacol Exp Ther; 1985 Mar; 232(3):770-4. PubMed ID: 3973826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of dihydrolysergic acid amide on serotonergic and alpha-adrenergic receptors in human blood platelets and femoral veins in vitro.
    Glusa E; Markwardt F
    Arch Int Pharmacodyn Ther; 1986 Oct; 283(2):303-11. PubMed ID: 3024599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
    Lucki I; Nobler MS; Frazer A
    J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Hydroxytryptamine(1A) receptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein.
    Cohen ML; Schenck KW; Hemrick-Luecke SH
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1195-201. PubMed ID: 10454495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. O-acylated lysergol and dihydrolysergol-I derivatives as competitive antagonists of 5-HT at 5-HT2 receptors of rat tail artery. Allosteric modulation instead of pseudoirreversible inhibition.
    Pertz H; Eich E
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Apr; 345(4):394-401. PubMed ID: 1320207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of serotonin receptors in isolated rat intramyocardial coronary artery.
    Lai FM; Tanikella T; Cervoni P
    J Pharmacol Exp Ther; 1991 Jan; 256(1):164-8. PubMed ID: 1988655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
    Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
    Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study.
    Felixsson E; Persson IA; Eriksson AC; Persson K
    Phytother Res; 2010 Sep; 24(9):1297-301. PubMed ID: 20148408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.